How Often Should You Get the Prevnar 20 Vaccine?

Most adults need just one dose of Prevnar 20 (PCV20), with no routine booster currently recommended. That single shot covers twenty strains of the bacterium that causes pneumococcal disease, and for the vast majority of people, one dose is the end of the road. Children follow a completely different schedule, receiving up to four doses in infancy and toddlerhood. The simplicity of the adult recommendation, though, tends to generate more confusion than it resolves, because many people remember an older era of pneumococcal vaccination that involved two separate vaccines given months apart.

The Adult Recommendation

If you are 50 or older and have never received a pneumococcal conjugate vaccine, the current U.S. guidance is straightforward: get one dose of PCV20. The same applies to adults aged 19 through 49 who have certain medical conditions that raise their risk of pneumococcal disease, such as chronic heart or lung disease, diabetes, HIV, or any condition that weakens the immune system. In late 2024, the CDC’s Advisory Committee on Immunization Practices expanded the recommendation to include all adults 50 and older, lowering the threshold from the previous age-65 cutoff.¹

For adults between 19 and 64 who do not have a qualifying risk condition, the vaccine is not routinely recommended at this time. But if you fall into the higher-risk group at any age above 19, the schedule is the same single dose.² No booster is currently part of the regimen. Clinical trials showed that a single intramuscular injection produced strong immune responses against all twenty pneumococcal serotypes covered by the vaccine.³

Why No Booster Is Recommended Yet

Conjugate vaccines, the class PCV20 belongs to, work by linking a piece of the bacterial sugar coat to a carrier protein. This combination trains your immune system in a way that tends to create longer-lasting memory than older polysaccharide-only vaccines. That memory is the reason a single adult dose has been considered sufficient so far. The immune response triggered by PCV20 appears durable enough that regulators have not seen a need to schedule a repeat dose.

That said, “no booster recommended” does not mean the question is permanently settled. Long-term follow-up studies are still accumulating data on how immunity holds up five, ten, and fifteen years after vaccination. If evidence eventually shows that protection wanes meaningfully, guidelines could change. For now, the science supports one dose, and you should not seek out additional doses on your own.

What If You Already Had an Older Pneumococcal Vaccine

This is where timing gets a little more involved. Before PCV20 arrived, the standard adult approach was a two-vaccine sequence: PCV13 (an earlier Prevnar product covering thirteen strains) followed by PPSV23 (a polysaccharide vaccine covering twenty-three strains). If you completed that full sequence, you are generally considered protected and do not need PCV20 on top of it. The seven extra strains in PCV20 that PCV13 did not cover are also included in PPSV23, so you already have coverage against them.

If you received PCV13 but never followed up with PPSV23, one dose of PCV20 can serve as your completion step, replacing the PPSV23 you missed. The recommended gap is at least one year after PCV13, though immunocompromised individuals can receive it as soon as eight weeks later.² If you received only PPSV23 in the past and never had a conjugate vaccine, one dose of PCV20 at least one year later fills the gap. And if your vaccination history is unknown, the simplest path is a single dose of PCV20, which covers all the bases in one shot.

The Pediatric Schedule Is Completely Different

Children receive Prevnar 20 on a multi-dose schedule that looks nothing like the adult regimen. The recommended series is four doses: the first can be given as early as six weeks of age, with the second and third doses spaced four to eight weeks apart, and a fourth dose at around twelve to fifteen months of age (at least two months after dose three).⁴ Young children’s immune systems need repeated exposures to build adequate protection, which is why the pediatric schedule involves multiple visits while adults can get by with one.

If your child missed doses or started the series late, catch-up schedules exist, but the details depend on the child’s age and how many doses they have already received. Your pediatrician can work through the specifics. The important thing for parents to understand is that the “one dose for adults” message does not apply to young children at all.

What PCV20 Actually Covers

Prevnar 20 targets twenty serotypes of Streptococcus pneumoniae, the bacterium behind most cases of bacterial pneumonia, meningitis, and bloodstream infections. It builds on the thirteen strains covered by the older PCV13 and adds seven more: serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F.⁵ Those additional serotypes were chosen because surveillance data showed they were responsible for a growing share of pneumococcal disease after widespread PCV13 use had pushed the original thirteen strains down. A systematic review covering studies from 2010 through 2020 found that the non-PCV13 serotypes included in PCV20 accounted for roughly 28% of invasive pneumococcal disease in children across the Americas, Europe, and the Western Pacific.⁶

This pattern of newer strains rising as older ones fall is called serotype replacement, and it has been observed since the first pneumococcal conjugate vaccine rolled out. Because the bacterium exists in over ninety serotypes, vaccinating against a subset inevitably leaves room for non-covered strains to fill the ecological niche.⁷ PCV20 was designed to address the most clinically relevant replacements that had emerged after PCV13 became standard, but the cycle could continue over time. Newer vaccines with even broader coverage (a 21-valent product, for example) are already being evaluated.

How Well Does One Dose Actually Work

The first large-scale real-world study of PCV20 effectiveness in U.S. adults 65 and older found that one dose reduced invasive pneumococcal disease by about 26% overall and all-cause community-acquired pneumonia by about 15%. The effect was strongest in the youngest group studied: adults 65 to 74 saw a roughly 35% reduction in invasive disease, while those 85 and older saw about a 17% reduction.⁸ Those numbers reflect the fact that pneumococcal disease has many causes beyond the twenty serotypes in the vaccine, and that older immune systems respond less robustly to vaccination in general.

It is worth putting those percentages in context. For every 100,000 vaccinated adults 65 and older over a year, the vaccine was estimated to prevent roughly 13 cases of invasive disease and 262 cases of community-acquired pneumonia.⁸ Pneumonia prevention is where the volume benefit lies. Invasive disease is rarer but far more dangerous, and even a modest percentage reduction saves lives at a population level.

Side Effects and What to Expect

PCV20’s tolerability profile is broadly similar to that of PCV13, which has decades of use behind it.³ The most common complaint is soreness at the injection site, followed by muscle pain and fatigue. Post-licensure safety monitoring through the U.S. Vaccine Adverse Event Reporting System confirmed this picture: among adults 19 to 64, injection-site reactions were reported in about 29% of adverse event reports, with pain, redness, and fever rounding out the list. For adults 65 and older, the pattern was similar, with injection-site reactions reported in about 35% of reports.⁹ These reactions are typically mild to moderate and resolve within a couple of days. Serious adverse events related to the vaccine have been rare in surveillance data.

Getting PCV20 Alongside Your Flu Shot

A common practical question is whether you can roll PCV20 into the same visit as your annual influenza vaccine. The answer is yes. A phase 3 trial tested co-administration of PCV20 with a quadrivalent flu vaccine and found that immune responses to both vaccines held up just as well when given together as when given separately. The antibody levels met the pre-set benchmarks for all twenty pneumococcal serotypes and all four influenza strains.¹⁰

Side effects were slightly more common when both shots were given at the same visit. Mild and moderate fatigue was reported more often in the co-administration group (about 20% mild and 12% moderate, versus 11-13% and 8-10% with separate shots). That difference was not considered clinically significant, and no serious adverse events were linked to the combination.¹⁰ From a convenience standpoint, combining the two in one visit removes a barrier to getting vaccinated, especially for people who find it difficult to schedule multiple appointments.

Why Many Eligible Adults Still Have Not Received It

Despite the simplicity of the one-dose schedule, pneumococcal vaccine uptake among adults has historically been uneven. Research on barriers has consistently found that many adults do not even know they need a pneumococcal vaccine, and some who are aware of it refuse unless their primary care doctor specifically recommends it.¹¹ Others carry a misconception that the vaccine itself can cause pneumonia or flu-like illness. Knowledge gaps about the necessity of adult vaccination in general are a persistent obstacle.¹²

The gaps in uptake are not distributed evenly. Black and Hispanic adults, people with lower household incomes, those without a college education, and residents of rural communities have all been found to receive pneumococcal vaccines at significantly lower rates than white, suburban, and higher-income adults.¹³ The same populations often carry a higher burden of pneumococcal disease itself, creating a double disadvantage.¹⁴

Community pharmacies have emerged as one way to close these gaps. Pharmacist-administered vaccination programs have reached high-risk patients at rates that outpace traditional clinical settings.¹⁵ In rural areas especially, where primary care visits may be less frequent, pharmacy-based immunization services increase access.¹⁶ If you are eligible and have been putting it off, a walk-in appointment at a pharmacy is often the fastest route.

How Other Countries Handle the Schedule

The one-dose PCV20 approach is not universal. Across the European Union, recommendations vary considerably. About two-thirds of EU countries that recommend a conjugate vaccine for adults use PCV20 alone, mirroring the U.S. approach. But roughly a quarter still use a sequential strategy, giving a conjugate vaccine followed by PPSV23, and another quarter recommend PPSV23 by itself without any conjugate vaccine at all.¹⁷ Countries like France, Germany, Belgium, and Sweden have adopted PCV20 as a standalone recommendation, while others like Austria and Italy still use the two-vaccine sequence. The differences reflect varying assessments of cost-effectiveness, local disease epidemiology, and how quickly national immunization programs update after new vaccine approvals.

Economic modeling in Germany found that a single dose of PCV20 for adults 60 and older (and younger adults with risk conditions) would reduce pneumococcal disease, save lives, and be cost-saving compared to the older sequential approach.¹⁸ U.S. cost-effectiveness models have been more variable, with estimates ranging widely depending on assumptions about how much indirect protection children’s vaccination already provides to adults and how long the vaccine’s protection lasts.¹ Even where the cost per quality-adjusted life-year is high in models, the practical takeaway for you as an individual is unchanged: the vaccine is covered by most insurance plans, and one dose is all you need.

When a Second Pneumococcal Vaccine Might Still Be Needed

There is one scenario where PCV20 does not close the book entirely. If your healthcare provider chose PCV15 (a competing fifteen-valent conjugate vaccine) instead of PCV20, you still need a follow-up dose of PPSV23 to broaden your serotype coverage. That follow-up should come at least one year later for most adults, or at least eight weeks later if you are immunocompromised.² This two-step sequence with PCV15 is the main reason some people still hear that pneumococcal vaccination requires “more than one shot.” If you received PCV20 specifically, that second step is unnecessary, because PCV20 already covers the additional serotypes that PPSV23 would have added.

If you are not sure which pneumococcal vaccine you received, your vaccination record or your provider’s office can clarify. It matters because the follow-up schedule is genuinely different depending on which product you got. The names sound similar enough that mix-ups happen, and asking is better than guessing.

1
Morbidity and Mortality Weekly Report. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years
2
PubMed Central. Recommendations on PCV20 vaccine in adults and at-risk populations
3
PubMed. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
4
PfizerPro. Prevnar 20 Dosing & Recommendations
5
PubMed. 20-Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval
6
PubMed Central. PCV20 in pediatric pneumococcal prevention: expanded coverage, remaining challenges
7
PubMed Central. Serotype replacement in disease after pneumococcal vaccination
8
PubMed Central. Real-World Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine among Adults 65-74, 75-84, and ≥85 Years of Age in the United States
9
PubMed Central. Post-licensure Safety Surveillance of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among US Adults in the Vaccine Adverse Event Reporting System (VAERS)
10
Vaccine. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine
11
Vaccine. A qualitative study to assess the perceived benefits and barriers to the pneumococcal vaccine in hospitalised older people
12
PubMed Central. Under-Vaccination in Adults: Qualitative Insights Into Perceived Barriers Reported by Vaccine Supporters, Undecided and Refuters
13
PubMed Central. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
14
PubMed Central. Health disparities in the burden of pneumococcal disease in US adults
15
Vaccine. Pharmacists as providers: Targeting pneumococcal vaccinations to high risk populations
16
PubMed Central. A Cross-Sectional Survey to Identify Current Pneumococcal Vaccination Practices and Barriers in Rural Community Pharmacies
17
PubMed Central. Pneumococcal vaccination offer and schedules in adults in EU countries: An update
18
PubMed. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany